- Home
- GBR vs LIXT Comparison
GBR vs LIXT Comparison
Compare GBR & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBR
- LIXT
- Stock Information
- Founded
- GBR 1978
- LIXT 2005
- Country
- GBR United States
- LIXT United States
- Employees
- GBR N/A
- LIXT N/A
- Industry
- GBR Oil & Gas Production
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- GBR Energy
- LIXT Health Care
- Exchange
- GBR Nasdaq
- LIXT Nasdaq
- Market Cap
- GBR 4.5M
- LIXT 4.1M
- IPO Year
- GBR N/A
- LIXT N/A
- Fundamental
- Price
- GBR $0.86
- LIXT $1.22
- Analyst Decision
- GBR
- LIXT
- Analyst Count
- GBR 0
- LIXT 0
- Target Price
- GBR N/A
- LIXT N/A
- AVG Volume (30 Days)
- GBR 35.8K
- LIXT 8.0K
- Earning Date
- GBR 05-20-2025
- LIXT 05-20-2025
- Dividend Yield
- GBR N/A
- LIXT N/A
- EPS Growth
- GBR N/A
- LIXT N/A
- EPS
- GBR N/A
- LIXT N/A
- Revenue
- GBR $146,000.00
- LIXT N/A
- Revenue This Year
- GBR N/A
- LIXT N/A
- Revenue Next Year
- GBR N/A
- LIXT N/A
- P/E Ratio
- GBR N/A
- LIXT N/A
- Revenue Growth
- GBR N/A
- LIXT N/A
- 52 Week Low
- GBR $0.67
- LIXT $1.02
- 52 Week High
- GBR $1.82
- LIXT $3.50
- Technical
- Relative Strength Index (RSI)
- GBR 61.52
- LIXT 47.63
- Support Level
- GBR $0.67
- LIXT $1.14
- Resistance Level
- GBR $0.87
- LIXT $1.31
- Average True Range (ATR)
- GBR 0.06
- LIXT 0.10
- MACD
- GBR 0.02
- LIXT -0.00
- Stochastic Oscillator
- GBR 90.81
- LIXT 29.00
About GBR New Concept Energy Inc
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations. It operates in one segment, which is real estate rental.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.